AACR 2022 | Strategies to enhance anti-tumor T cell response to immune checkpoint inhibitors in TNBC

Lisa A. Carey, MD, FASCO, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, discusses strategies to improve and enhance anti-tumor T cell response to immune checkpoint inhibitors (ICIs) in triple negative breast cancer (TNBC). Combinatorial strategies for ICIs in breast cancer are already common practice in breast cancer treatment, as it is well-documented that chemotherapy acts synergistically with ICI therapy. Currently about 40% of TNBCs are immune activated and it is hoped that new combinations of ICIs with radiotherapies or novel treatments can manifest a strategy for the remaining 60% of resistant pathologies. This interview took place at the American Association for Cancer Research Annual Meeting in New Orleans, LA.